Thereby, HIFs regulate a multitude of functional pathways that can impact tumor activity, such as tumor vascularization via vascular endothelial growth factor (VEGF) [6], tumor metabolism via solute carrier family 2 member 1 (SLC2A1, better known as GLUT-1) [8] and Aldolase-C expression [9], and tumor motility and invasiveness via loss of E-cadherin and activation of Wnt/beta-catenin signaling [10, 11]. The gene discussed is SLC1A2; the disease is neoplasm.